Translational Drug Library Screening

The following compounds were used: entinostat (Biomol GmbH, M4693-15A.25), idasanutlin (TargetMol; T6254), olaparib (BIOZOL; S1060), ribociclib (supplier), selinexor (BioCat; T6106-TM), vinblastinesulfate (Selleckchem; S4505), doxorubicin in 0.9% NaCl (UKHD pharmacy), niraparib (Selleckchem; S2741), pamiparib (Selleckchem; S8592), veliparib (Selleckchem; S1004). The translational drug library for initial drug selection comprised 74 compounds [19 (link)].

Free full text: Click here

Vollmer J., Ecker J., Hielscher T., Valinciute G., Ridinger J., Jamaladdin N., Peterziel H., van Tilburg C.M., Oehme I., Witt O, & Milde T. (2023). Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells. Journal of Neuro-Oncology, 164(3), 617-632.

Publication 2023

olaparib niraparib pamiparib veliparib

0 9 nacl Doxorubicin Drug drug Entinostat Idasanutlin Library Niraparib Olaparib Pamiparib Ribociclib Selinexor Translational Veliparib

Corresponding Organization : Hopp Children's Cancer Center Heidelberg

Other organizations : St. Jude Children's Research Hospital

Top 5 similar protocols

Variable analysis

independent variables

Entinostat
Idasanutlin
Olaparib
Ribociclib
Selinexor
Vinblastinesulfate
Doxorubicin
Niraparib
Pamiparib
Veliparib

dependent variables

Measured outcomes

control variables

0.9% NaCl

controls

Positive controls not explicitly mentioned.
Negative controls not explicitly mentioned.

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!